~~<i id='A85C5D7ABF'><strike id='A85C5D7ABF'><tt id='A85C5D7ABF'><pre id='A85C5D7ABF'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：leisure time 2025-09-27 09:24:52 Page View：93241

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： YouTube cracks down on misinformation on cancer treatment
Next article： Medical records are filled with copy

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Pediatricians' group reaffirms support for gender

Aprotestorwearsatransgenderflagatahearingonbanninggender-affirminghealthcarelegislationinMissouri.AP

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Health AI: on the border between health care and tech

AdobeThere’sbeensignificantinvestmentincompaniescreatingartificialintelligence(AI)applicationsforhea